BANK VONTOBEL/CALL/MODERNA/105/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 02:01:59 2024-06-26 pm EDT | ||
| 2.31 EUR | -31.66% |
|
| Current month | -11.98% | ||
| 1 month | -45.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 2.31 | -31.66% |
| 24-06-25 | 3.38 | +1.81% |
| 24-06-24 | 3.32 | +4.73% |
| 24-06-21 | 3.17 | -0.63% |
| 24-06-20 | 3.19 | +7.05% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 02:01 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VM7NKV |
| ISIN | DE000VM7NKV1 |
| Date issued | 2023-12-29 |
| Strike | 105 $ |
| Maturity | 2024-09-20 (86 Days) |
| Parity | 10 : 1 |
| Emission price | 1.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.18 € |
|---|---|
| Lowest since issue | 0.79 € |
| Spread | 0.02 € |
| Spread % | 0.88% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Warrants
- Warrant
